Kavli Affiliate: Charles Rice
| Authors: Fengwen Zhang, Jesse Jenkins, Renan V.H. de Carvalho, Sandra Nakandakari-Higa, Teresia Chen, Morgan E Abernathy, Elisabeth Nyakatura, David Andrew, Irina V. Lebedeva, Ivo C Lorenz, H.-Heinrich Hoffmann, Charles M. Rice, Gabriel D. Victora, Christopher O. Barnes, Theodora Hatziioannou and Paul D Bieniasz
| Summary:
Abstract Human monoclonal antibodies from convalescent individuals that target the SARS-CoV-2 spike protein have been deployed as therapeutics against SARS-CoV-2. However, nearly all of these antibodies have been rendered obsolete by SARS-CoV-2 variants that evolved to resist similar, naturally occurring antibodies. Here, we describe the development of human monoclonal antibodies that bind the ACE2 receptor rather than the viral spike protein. These antibodies block infection by all ACE2 binding sarbecoviruses, including emergent SARS-CoV-2 variants. Structural and biochemical analyses revealed that the antibodies target an ACE2 epitope that engages SARS-CoV-2 spike. Importantly, the antibodies do not inhibit ACE2 enzymatic activity, nor do they induce ACE depletion from cell surfaces. The antibodies exhibit favorable pharmacology and protect human ACE2 knock-in mice against SARS-CoV-2 infection. Such antibodies should be useful prophylactic and treatment agents against any current and future SARS-CoV-2 variants, as well as ACE2-binding sarbecoviruses that might emerge as future pandemic threats. Competing Interest Statement The Rockefeller University has filed a patent application for anti-hACE2 antibodies on which F.Z., T.H. and P.D.B. are listed as inventors.